Table 4. The logistics regression analysis of the factors associated with brain necrosis recurrence.
P value | |
---|---|
Gender | 0.84 |
Age | 0.87 |
Bevacizumab treatment history | 0.40 |
BED | 0.73 |
Primary tumor location | 0.79 |
The medication cycles of first course with bevacizumab | 0.46 |
Volume of necrosis before bevacizumab treatment | 0.92 |
Residual necrosis after the first course bevacizumab treatment | 0.38 |
Follow up time after the first course bevacizumab treatment | 0.032 |